Camptothecin - BlueLink Pharmaceuticals

Drug Profile

Camptothecin - BlueLink Pharmaceuticals

Alternative Names: CRLX 101; Cyclosert™-enhanced camptothecin; IT-101

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Insert Therapeutics
  • Developer AstraZeneca; Beth Israel Deaconess Medical Center; BlueLink Pharmaceuticals; Brigham and Womens Hospital; Cerulean Pharma; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Cancer Institute (USA); University of North Carolina
  • Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase I/II Solid tumours
  • Preclinical Breast cancer
  • No development reported Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 02 Jul 2017 Phase-II clinical trials in Rectal cancer (Combination therapy, Late-stage disease, Neoadjuvant therapy) in USA (IV), before June 2017 (NCT02010567)
  • 02 Jun 2017 Interim efficacy and adverse events data from a phase Ib/II trial in Rectal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 20 Mar 2017 Cerulean enters into an agreement with BlueLink Pharmaceuticals to sell camptothecin (CRLX 101) and docetaxel (CRLX 301)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top